Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COG-101
- Development stage
- Preclinical
- Lead developer
- Cognigenics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
COG-101 is a preclinical-stage CRISPR-based gene therapy being developed by Cognigenics for the treatment of Generalized Anxiety Disorder (GAD) and the enhancement of cognitive function. The therapeutic utilizes a CRISPR-based molecular architecture delivered via intranasal lipid nanoparticles (LNPs), a route designed to facilitate direct access to the central nervous system while bypassing the blood-brain barrier. By employing CRISPR technology, COG-101 aims to achieve precise and potentially long-lasting modulation of genetic targets involved in neurocircuitry regulation and psychiatric health. The program is currently in the preclinical phase of development.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on COG-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COG-101.